Description
BK-2C-B
BK-2C-B, Substituted phenetylamines are among the most popular research materials, although this family is very broad and contains diverse reagents with unique pharmacological footprints. Recent emergence of BK-2C-B as a viable replacement for some of the unavailable materials from this group has understandably caused researchers from around the world to show interest. The substance is believed to possess a combination of psychedelic and stimulant traits, presenting a unique riddle that must be solved in the laboratory. As a beta-keto variation of 2C-B, this chemical can be classified as a substituted cathinone and it is closely related to another valuable research agent, BOB.
The molecule of BK-2C-B is based on a phenyl ring with an attached amino group, and also includes a ketone group and two methoxy groups. This structure is responsible for its suspected role as a partial agonist of the 5HT-2A receptors, and possibly for other biochemical interactions. It is important to note that this chemical is almost completely untested and that more detailed quantitative analysis needs to be conducted before full potentials of this compound are properly understood.
BK-2C-B is a psychedelic, structurally similar to 2C-B and displaying similar properties.
As such, it is an ideal substitute for the banned 2-CB, in cases of research programmes studying the effects of that hallucinogenic upon different receptors.
Available in both powder and pellet form, BK-2C-B offers a longer experience than 2-CB, reported to be up to 10 hours, and is sold for in vitro research purposes only.
Healthplus Research Chemicals are European based company specializing in retails and wholesale distribution of the best Re-find Research Chemicals.
Since our founding, we have been developing a vast catalog of products to meet the needs of our customers. We have grown our capabilities to include active pharmaceutical ingredient manufacturing, forensic analytical standard production, contract research service expertise, pre-clinical drug development,
